Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok). LSALT Peptide is developed for targeting organ inflammation often experienced in hospitalized COVID-19 patients. It focuses on therapeutic development of LSALT Peptide and other DPEP-1 targeting drug candidates for new indications where inflammation of the lungs, liver and kidneys is an unmet problem. It has additional technology platforms in its portfolio including AB569, which focuses on preventing antibiotic resistant bacterial infections; Borg, which is a peptide-solid surface interface, and MetaMx, which is a synthetic molecule that target brain tumor initiating cells and invasive glioma cells.

TSXV:ARCH - Post by User

Arch Biopartners Inc > Arch Biopartners - My Due Diligence (NEW)

<< Previous

Bullboard Posts

Next >>

Comment by wethenorthhon Dec 02, 2021 1:27pm

59 Views

Post# 34191014

RE:Arch Biopartners - My Due Diligence (NEW)

Thanks Riverfolk, certainly super helpful DD.

Market will understand at some point how big this drug is and start chasing as this company keeps overachieving.

No dilution for a phase 3 trial? Who would have thought LOL. You got to be real dumb to be selling right now with all that this company has going on.

Oh well, makes the ride to $10+ that much easier :)

<< Previous

Bullboard Posts

Next >>

What is the gold outlook for the rest of 2024?